高级前列腺癌表观遗传调控的建立。
SETting Up for Epigenetic Regulation of Advanced Prostate Cancer.
机构信息
Department for BioMedical Research, University of Bern, Switzerland.
Department for BioMedical Research, University of Bern, Switzerland; Bern Center for Precision Medicine, University of Bern and Inselspital, Bern, Switzerland.
出版信息
Cancer Cell. 2020 Sep 14;38(3):309-311. doi: 10.1016/j.ccell.2020.08.009.
Abstract
An outgrowth of therapy-resistant prostate cancers (PCa) with enhanced metastatic potential may be triggered by inhibitors of androgen receptor (AR) signaling, often via epigenetic rewiring. In this issue of Cancer Cell, Yuan et al. demonstrate how SETD2 integrates EZH2 and AMPK signaling pathways to keep PCa metastasis in check.
摘要
治疗抵抗性前列腺癌（PCa）的生长可能会受到雄激素受体（AR）信号抑制剂的触发，这种抑制剂通常通过表观遗传重排来增强转移潜能。在本期《癌细胞》杂志中，Yuan 等人展示了 SETD2 如何整合 EZH2 和 AMPK 信号通路来抑制 PCa 的转移。
相似文献
1
SETting Up for Epigenetic Regulation of Advanced Prostate Cancer.高级前列腺癌表观遗传调控的建立。
Cancer Cell. 2020 Sep 14;38(3):309-311. doi: 10.1016/j.ccell.2020.08.009.
2
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.SETD2 通过整合 EZH2 和 AMPK 信号通路来限制前列腺癌转移。
Cancer Cell. 2020 Sep 14;38(3):350-365.e7. doi: 10.1016/j.ccell.2020.05.022. Epub 2020 Jul 2.
3
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.抑制增强子的外显子 2（EZH2）可克服去势抵抗性前列腺癌对恩杂鲁胺的耐药性。
J Biol Chem. 2019 Jun 21;294(25):9911-9923. doi: 10.1074/jbc.RA119.008152. Epub 2019 May 13.
4
Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.雄激素受体通过激活增强子的 zeste 同源物 2 介导的 Wnt/β-连环蛋白信号转导促进肝细胞癌发生。
EBioMedicine. 2018 Sep;35:155-166. doi: 10.1016/j.ebiom.2018.08.043. Epub 2018 Aug 24.
5
Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.多梳抑制复合物蛋白 EZH2 和 EED 直接调控晚期前列腺癌中的雄激素受体。
Int J Cancer. 2019 Jul 15;145(2):415-426. doi: 10.1002/ijc.32118. Epub 2019 Feb 12.
6
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.雄激素受体开关是导致治疗抵抗性前列腺癌谱系不忠实的基础。
Nat Cell Biol. 2021 Sep;23(9):1023-1034. doi: 10.1038/s41556-021-00743-5. Epub 2021 Sep 6.
7
The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.植物化学物 3,3'-二吲哚甲烷通过抑制性染色质修饰降低 AR 控制的 DNA 损伤修复基因的表达，并与前列腺癌细胞中的 DNA 损伤有关。
J Nutr Biochem. 2017 Sep;47:113-119. doi: 10.1016/j.jnutbio.2017.05.005. Epub 2017 May 25.
8
Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.异常激活的 HOTAIR/EZH2/miR-193a 反馈环在前列腺癌进展中的作用。
J Exp Clin Cancer Res. 2017 Nov 15;36(1):159. doi: 10.1186/s13046-017-0629-7.
9
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.KDM8/JMJD5 作为 AR 和 PKM2 的双重共激活因子，整合了 CRPC 中的 AR/EZH2 网络和肿瘤代谢。
Oncogene. 2019 Jan;38(1):17-32. doi: 10.1038/s41388-018-0414-x. Epub 2018 Aug 2.
10
RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.RUNX1是一种受雄激素和EZH2调控的基因，在雄激素依赖和非依赖的前列腺癌中具有不同作用。
Oncotarget. 2015 Feb 10;6(4):2263-76. doi: 10.18632/oncotarget.2949.
引用本文的文献
1
Structure and function of the lysine methyltransferase SETD2 in cancer: From histones to cytoskeleton.赖氨酸甲基转移酶SETD2在癌症中的结构与功能：从组蛋白到细胞骨架
Neoplasia. 2025 Jan;59:101090. doi: 10.1016/j.neo.2024.101090. Epub 2024 Nov 25.
2
Exploring The Prognostic Significance of SET-Domain Containing 2 (SETD2) Expression in Advanced and Castrate-Resistant Prostate Cancer.探索含SET结构域蛋白2（SETD2）表达在晚期及去势抵抗性前列腺癌中的预后意义
Cancers (Basel). 2024 Apr 8;16(7):1436. doi: 10.3390/cancers16071436.
3
H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets.男性泌尿生殖系统癌症中的H3组蛋白甲基化格局：从分子机制到表观遗传生物标志物和治疗靶点。
Front Cell Dev Biol. 2023 May 9;11:1181764. doi: 10.3389/fcell.2023.1181764. eCollection 2023.
4
SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.SMYD3通过EZH2甲基化调控胃癌进展和巨噬细胞极化。
Cancer Gene Ther. 2023 Apr;30(4):575-581. doi: 10.1038/s41417-022-00535-5. Epub 2022 Sep 20.
5
Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.靶向蛋白激酶和表观遗传调控作为晚期前列腺癌治疗的联合治疗选择
Pharmaceutics. 2022 Feb 25;14(3):515. doi: 10.3390/pharmaceutics14030515.
本文引用的文献
1
The DNA methylation landscape of advanced prostate cancer.晚期前列腺癌的 DNA 甲基化图谱。
Nat Genet. 2020 Aug;52(8):778-789. doi: 10.1038/s41588-020-0648-8. Epub 2020 Jul 13.
2
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.SETD2 通过整合 EZH2 和 AMPK 信号通路来限制前列腺癌转移。
Cancer Cell. 2020 Sep 14;38(3):350-365.e7. doi: 10.1016/j.ccell.2020.05.022. Epub 2020 Jul 2.
3
Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.前列腺小细胞癌的治疗模式与结局：一项国家癌症数据库分析。
Prostate. 2019 Sep;79(12):1457-1461. doi: 10.1002/pros.23864. Epub 2019 Jul 11.
4
Genomic correlates of clinical outcome in advanced prostate cancer.晚期前列腺癌的临床结局的基因组相关性。
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.
5
The long tail of oncogenic drivers in prostate cancer.前列腺癌中致癌驱动基因的长尾现象。
Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2.
6
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.AMPK 对 EZH2 的磷酸化抑制 PRC2 甲基转移酶活性和致癌功能。
Mol Cell. 2018 Jan 18;69(2):279-291.e5. doi: 10.1016/j.molcel.2017.12.024.
7
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.去势抵抗性神经内分泌前列腺癌的不同克隆进化
Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8.
8
Targeting EZH2 in cancer.在癌症中靶向EZH2
Nat Med. 2016 Feb;22(2):128-34. doi: 10.1038/nm.4036.
9
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.在去势抵抗性前列腺癌细胞中，EZH2 致癌活性是独立于 Polycomb 的。
Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.
10
The polycomb group protein EZH2 is involved in progression of prostate cancer.多梳蛋白家族成员EZH2参与前列腺癌的进展。
Nature. 2002 Oct 10;419(6907):624-9. doi: 10.1038/nature01075.
Zotero 插件